In addition, other PD-1 inhibitors, such as tirelizumab and carrelizumab, and PD-L1 inhibitors, such as atirizumab, valileumab, and avelumab, have shown encouraging efficacy in clinical trials as HCC therapies (115). Here, CD274 is linked to hepatocellular carcinoma.